Effects of the substituted (S)-3-phenylpiperidine (-)-OSU6162 on PET measurements of [11C]SCH23390 and [11C]raclopride binding in primate brains (Q48224963)

From Wikidata

Jump to navigation Jump to search

scientific article published in March 1999

Language	Label	Description	Also known as
English	Effects of the substituted (S)-3-phenylpiperidine (-)-OSU6162 on PET measurements of [11C]SCH23390 and [11C]raclopride binding in primate brains	scientific article published in March 1999

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/10219971

Effects of the substituted (S)-3-phenylpiperidine (-)-OSU6162 on PET measurements of [11C]SCH23390 and [11C]raclopride binding in primate brains (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/10219971

Bengt Långström

8

object named as

Långström B

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

author name string

Ekesbo A

1

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/10219971

Torstenson R

2

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/10219971

Hartvig P

3

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/10219971

Carlsson A

4

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/10219971

Sonesson C

5

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/10219971

Waters N

6

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/10219971

Tedroff J

7

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/10219971

publication date

1 March 1999

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/10219971

Neuropharmacology

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/10219971

38

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/10219971

3

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/10219971

331-338

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/10219971

Parkinson's disease: pathophysiology

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900200-7

7 January 2021

Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: correlative evaluation by positron emission tomography and plasma prolactin levels

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900200-7

7 January 2021

Dopamine-induced recruitment of dopamine D1 receptors to the plasma membrane

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900200-7

7 January 2021

Dopamine in schizophrenia: a review and reconceptualization

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900200-7

7 January 2021

Striatal binding of the PET ligand 11C-raclopride is altered by drugs that modify synaptic dopamine levels

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900200-7

7 January 2021

(-)-OSU 6162 inhibits levodopa-induced dyskinesias in a monkey model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900200-7

7 January 2021

Chronic levodopa treatment alters basal and dopamine agonist-stimulated cerebral glucose utilization.

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900200-7

7 January 2021

Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900200-7

7 January 2021

Bromine-76 and carbon-11 labelled NNC 13-8199, metabolically stable benzodiazepine receptor agonists as radioligands for positron emission tomography

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900200-7

7 January 2021

Human dopamine receptor subtypes--in vitro binding analysis using 3H-SCH 23390 and 3H-raclopride

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900200-7

7 January 2021

Preparation of 11C-labelled SCH 23390 for the in vivo study of dopamine D-1 receptors using positron emission tomography

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900200-7

7 January 2021

A preliminary evaluation of the Scanditronix PC2048-15B brain scanner

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900200-7

7 January 2021

SCH 23390—The first selective dopamine D-1 antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900200-7

7 January 2021

Reserpine-induced reduction of in vivo binding of SCH 23390 and N-methylspiperone and its reversal by d-amphetamine

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900200-7

7 January 2021

Long-term effects of tetrabenazine in hyperkinetic movement disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900200-7

7 January 2021

A-77636: a potent and selective dopamine D1 receptor agonist with antiparkinsonian activity in marmosets

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900200-7

7 January 2021

Attempted use of haloperidol in the treatment of L-dopa induced dyskinesias

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900200-7

7 January 2021

An increase in the in vivo binding of [3H]SCH 23390 induced by MK-801 in the mouse striatum

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900200-7

7 January 2021

Performance characteristics of an eight-ring whole body PET scanner

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900200-7

7 January 2021

Specific in vitro and in vivo binding of 3H-raclopride. A potent substituted benzamide drug with high affinity for dopamine D-2 receptors in the rat brain

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900200-7

7 January 2021

Receptor basis for dopaminergic supersensitivity in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900200-7

7 January 2021

Repeated L-dopa administration reduces the ability of dopamine storage and abolishes the supersensitivity of dopamine receptors in the striatum of intact rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900200-7

7 January 2021

Synthesis of [11C-methyl]-(-)-OSU6162, its regional brain distribution and some pharmacological effects of (-)-OSU6162 on the dopaminergic system studied in the rhesus monkey by positron emission tomography

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900200-7

7 January 2021

Levodopa-induced dyskinesia: review, observations, and speculations

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900200-7

7 January 2021

Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET.

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900200-7

7 January 2021

Endogenous dopamine lowers the dopamine D2 receptor density as measured by [3H]raclopride: implications for positron emission tomography of the human brain

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900200-7

7 January 2021

Substituted (S)-phenylpiperidines and rigid congeners as preferential dopamine autoreceptor antagonists: synthesis and structure-activity relationships.

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900200-7

7 January 2021

Antiparkinsonian actions of glutamate antagonists--alone and with L-DOPA: a review of evidence and suggestions for possible mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900200-7

7 January 2021

Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET.

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900200-7

7 January 2021

In vivo striatal binding of the D1 antagonist SCH 23390 is not modified by changes in dopaminergic transmission

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900200-7

7 January 2021

Effects of endogenous dopamine on kinetics of [3H]N-methylspiperone and [3H]raclopride binding in the rat brain

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900200-7

7 January 2021

Identifiers

10.1016/S0028-3908(98)00200-7

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/10219971

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/10219971

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48224963&oldid=2190977494"